Category: Politics and Regulation
The CAM Docket: Boiron II
Five consumer lawsuits are pending in the U.S. against Boiron, the world’s largest manufacturer of homeopathic products. One lawsuit is also pending in Canada. As reported in a previous post, the U.S. plaintiffs claim they purchased homeopathic products, such as Coldcalm, Oscillo, Arnicare and Chestal Cough Syrup, based on Boiron’s misleading and false statements that they are effective for various ailments. Therefore,...
Cancer care in the U.S. versus Europe: Is more necessarily better?
The U.S. is widely known to have the highest health care expenditures per capita in the world, and not just by a little, but by a lot. I’m not going to go into the reasons for this so much, other than to point out that how to rein in these costs has long been a flashpoint for debate. Indeed, most of the...
The “CAM” Consumer: Misled and Abused
There is a disturbing lack of protection for the consumer of “complementary and alternative” products and services. I can think of no other area of commerce where misleading, as well as out and out false, information is so regularly employed, without consequence, to entice the consumer into forking over his hard-earned cash. Nor do I know of any other manner of goods...
California Bill AB 2109: The Antivaccine Movement Attacks School Vaccine Mandates Again
AB 2109 in California makes it harder for parents to claim personal belief exemptions to school vaccine requirements by requiring that parents visit a physician or other enumerated health care provider to counsel them on the risks of leaving their child unvaccinated, thus providing informed consent. Not surprisingly, antivaxers do not like it.
The CAM Docket: Boiron I
Author’s note: This will inaugurate a series of occasional posts observing the wheels of justice grind slowly over “CAM.” In a previous post, I posited that CAM practitioners might well subject themselves to liability for the tort of fraudulent misrepresentation. This misrepresentation could be based on both the lack of scientific evidence of effectiveness and the lack of scientific plausibility for their...
Disparities in Regional Health Care Costs
In 2009, during the “Obamacare” debate that was dominating the news, Atul Gawande wrote an article in the New Yorker that was widely praised and cited, including by president Obama himself. The article is a thought-provoking discussion of why some communities in the US have much higher health care costs than other regions. I took two main conclusions from the article. The...
An antivaccine tale of two legal actions
I don’t know what it is about the beginning of a year. I don’t know if it’s confirmation bias or real, but it sure seems that something big happens early every year in the antivaccine world. Consider. As I pointed out back in February 2009, in rapid succession Brian Deer reported that Andrew Wakefield had not only had undisclosed conflicts of interest...
FDA versus Big Supp: Rep. Burton to the Rescue (Again)
The Dietary Supplement Health and Education Act of 1994 (DSHEA) has been aptly described here at SBM as a travesty of a mockery of a sham. The supplement industry’s slick marketing, herb adulteration due to lack of pre-market controls, Quack Miranda Warning, and the many supplements for which claims of effectiveness failed to hold up under scientific scrutiny (e.g., antioxidants, collagen, glucosamine...
Bravewell Bimbo Eruptions
This is yet another response to the recent “Integrative Medicine in America” report published by the Bravewell Collaborative. Drs. Novella and Gorski have already given that report its due, so I won’t repeat the background information. Inevitably, I’ll cover some of the same points, but I’ll also try to emphasize a few that stand out to me. Most of these have been...
“Obama Promises $156 Million to Alzheimer’s…But where will the money come from?” That’s easy: the NCCAM!
The quoted language above is part of the headline of this story in today’s The Scientist: Citing the rising tide of Americans with Alzheimer’s—projections suggest 10 million people will be afflicted by 2050—the Obama administration and top National Institutes of Health officials are taking action. On February 7, they announced that they will add an additional $80 million to the 2013 NIH...